权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Pre-Clinical Development of Nuclease Mediated Gene Therapy for SCID

SCID 核酸酶介导基因疗法的临床前开发

基本信息

批准号：
9173450
负责人：
Matthew H Porteus
金额：
$ 39.44万
依托单位：
STANFORD UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2012
资助国家：
美国
起止时间：
2012-12-01 至 2017-11-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9173450
关键词：
Alleles Alpha Cell Basic Science Biological Assay Bone Marrow Transplantation CD34 gene Cell Line Cells Child Chromatin Chromatin Structure Chronic Clinical Clinical Trials Development Disease Engineering Exons Failure Fibroblasts Foundations Frequencies Gene Frequency Gene Targeting Gene-Modified Generations Genes Genome Goals Hematopoietic Stem Cell Transplantation Hematopoietic stem cells Hereditary Disease Human IL2RG gene Iatrogenesis Immune Immune system Infection Insertional Activations K562 Cells Life Lymphoid Mediating Methods Modification Mus Mutation Oncogenic Patients Pattern Probability Proteins Proto-Oncogenes Regulation Retroviral Vector Risk Severe Combined Immunodeficiency Siblings Site Stem cells System Testing Therapeutic Therapy trial Transgenes Translating Transplantation Umbilical Cord Blood Viral Viral Vector alpha-Thalassemia cell type clinically relevant experimental study gene therapy gene therapy clinical trial genome analysis genome-wide homologous recombination improved innovation leukemia lymphoblastoid cell line man next generation nuclease pre-clinical preclinical development promoter public health relevance reconstitution success tumorigenesis whole genome

项目摘要

DESCRIPTION (provided by applicant): The severe combined immunodeficiencies (SCID) are a set of genetic diseases in which patients are born with mutations in single genes and are unable to develop functional immune systems. While bone marrow transplantation can be curative for these diseases there remain significant limitations to this approach. Gene therapy using retroviral vectors have been used for SCID with mixed results. Tens of patients have developed functional immune systems such that they can live without having to worry about developing life-threatening infections. A handful of patients, however, have developed iatrogenic leukemia from the insertional activation of a proto-oncogene. In the next generation of viral based gene therapy trials for these diseases, the viral vectors have been engineered to decrease the probability of activating proto- oncogenes. The results of these trials, particularly the oncogenic risk, will not be known for several years. We have been working towards a third generation gene therapy approach to SCID. In contrast to using viral vectors to deliver transgenes in an uncontrolled fashion, we are working towards using homologous recombination to precisely modify the genome. We have shown that using engineered nucleases we can stimulate gene modification by homologous recombination ("gene targeting") at frequencies that should be therapeutically useful (>10%) in cell lines and primary cels. The overall focus of the proposal is to translate the findings in a methodical and careful fashion to use in patient-derived umbilical cord blood derived CD34+ cells. The three specific aims are focused on translating our basic science studies into a clinical trial. Specific aim 1 is focused o developing nuclease mediated gene targeting for the IL2RG gene. Specific aim 2 is focused on developing nuclease mediated gene targeting for the ADA gene. Specific aim 3 is focused on using whole genome approaches to better understand nuclease on-target activity and off-target effects. Our goal with this proposal is to complete the IND-enabling experiments necessary to initiate a first-in-man gene therapy clinical trial using homologous recombination to cure SCID.

描述（由申请人提供）：严重联合免疫缺陷（SCID）是一组遗传性疾病，患者出生时具有单基因突变，无法发育功能性免疫系统。虽然骨髓移植可以治愈这些疾病，但这种方法仍然有很大的局限性。利用逆转录病毒载体进行基因治疗已被用于SCID，但结果好坏参半。数十名患者已经开发出功能性免疫系统，这样他们就可以不必担心发生危及生命的感染。然而，少数患者因插入激活原癌基因而发展为医源性白血病。在这些疾病的下一代基于病毒的基因治疗试验中，病毒载体已经被设计成降低激活原癌基因的可能性。这些试验的结果，特别是致癌风险，将在几年内不得而知。我们一直致力于开发第三代SCID基因治疗方法。与使用病毒载体以不受控制的方式传递转基因不同，我们正致力于使用同源重组来精确地修饰基因组。我们已经证明，使用工程核酸酶，我们可以通过同源重组（“基因靶向”）刺激基因修饰，在细胞系和原代细胞中，频率应该是治疗有用的（bb0 - 10%）。该提案的总体重点是以一种有系统和谨慎的方式将这些发现转化为用于患者来源的脐带血来源的CD34+细胞。这三个具体目标的重点是将我们的基础科学研究转化为临床试验。特异性目标1集中于开发靶向IL2RG基因的核酸酶介导基因。特异性目标2的重点是开发核酸酶介导的基因靶向ADA基因。具体目标3侧重于使用全基因组方法来更好地了解核酸酶的靶活性和脱靶效应。我们提出这一建议的目标是完成必要的ind启用实验，以启动使用同源重组治疗SCID的首次人体基因治疗临床试验。